Accolade (NASDAQ:ACCD) Announces Quarterly Earnings Results, Beats Estimates By $0.14 EPS

Accolade (NASDAQ:ACCDGet Free Report) released its quarterly earnings data on Tuesday. The company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.44) by $0.14, Briefing.com reports. The business had revenue of $106.40 million during the quarter, compared to the consensus estimate of $104.87 million. Accolade had a negative net margin of 20.62% and a negative return on equity of 20.30%. The business’s revenue was up 9.8% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.43) EPS. Accolade updated its FY 2025 guidance to EPS and its Q3 2025 guidance to EPS.

Accolade Stock Performance

Shares of ACCD opened at $3.90 on Thursday. Accolade has a one year low of $3.35 and a one year high of $15.36. The company has a debt-to-equity ratio of 0.48, a quick ratio of 2.80 and a current ratio of 2.80. The stock has a market cap of $312.03 million, a P/E ratio of -3.36 and a beta of 1.99. The stock has a 50-day moving average of $4.02 and a two-hundred day moving average of $5.80.

Analyst Ratings Changes

Several analysts have recently issued reports on ACCD shares. Needham & Company LLC restated a “buy” rating and set a $8.00 target price on shares of Accolade in a research report on Monday. Barclays cut their target price on Accolade from $5.50 to $5.00 and set an “equal weight” rating on the stock in a research report on Wednesday. Stifel Nicolaus cut their price objective on shares of Accolade from $13.00 to $8.00 and set a “buy” rating on the stock in a research report on Friday, June 28th. Guggenheim reduced their price objective on shares of Accolade from $13.00 to $6.00 and set a “buy” rating on the stock in a research report on Friday, June 28th. Finally, Truist Financial reduced their target price on Accolade from $9.00 to $7.50 and set a “buy” rating on the stock in a research note on Wednesday. Three investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $9.38.

Read Our Latest Analysis on Accolade

About Accolade

(Get Free Report)

Accolade, Inc, together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based technology and multimodal support from a team of health assistants and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women's health specialists, case management specialists, expert medical opinion providers, and virtual primary care physicians.

Featured Articles

Earnings History for Accolade (NASDAQ:ACCD)

Receive News & Ratings for Accolade Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accolade and related companies with MarketBeat.com's FREE daily email newsletter.